Manufacturing It’s better
together
Cell and gene therapies are altering what’s possible in the world of medicine – but the scope of their implementation depends on the scale of manufacturing. It is to this end that organisations looking to make their mark in the field of cell and gene therapies have taken a collaborative approach to figuring out best practices. In an industry where every company has traditionally looked to gain a competitive advantage, Andrea Valentino speaks to Courtney Silverthorn of the Foundation for the National Institutes of Health, and Professor Kelvin Lee at the National Institute for Innovation in Manufacturing Biopharmaceuticals, to learn why teamwork may be the future.
iven it could soon revolutionise medicine, gene therapy has a surprisingly short history. Watson and Crick demonstrated the molecular structure of DNA in 1953 and scientists speculated it could cure genetic disorders by the early 1960s. But in reality, these principles have only practically been applied over the last few decades. Now used to combat everything from haemophilia and immune deficiencies to blindness, genes have the ability to upend our assumptions about incurable illnesses – along the way transforming our understanding of life’s building blocks.
G 38
No wonder the global market for cell and gene therapies (CGT) is already worth $7.5bn, with one recent study expecting it to enjoy CAGR of nearly 20% through 2030. Yet, amid all this potential, the practicalities of getting new CGTs from labs to patients is far from simple. In large part, this is simply down to the complex nature of the therapies themselves, involving as they do the subtle manipulation of cells and genes. The individualised nature of this work – some genetic mutations only impact tiny numbers of people – also makes manufacturing difficult.
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Anusorn Nakdee/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49
